Replimune REPL
NASDAQ REPL
$11.90 +0.48 (+4.16%)
As of: Oct 21, 2026 · 1:08 PM EDT

Replimune (REPL) Net Margin (2017 - 2018)

Updated

Analysis

Replimune (REPL) Net Margin (2017 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,133.02 Bn 1,101.60 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 616.49 Bn 535.01 Bn 17.26 Bn 21.86%
3 AbbVie 501.09 Bn 474.20 Bn 12.70 Bn 21.27%
4 Merck 366.78 Bn 321.16 Bn 12.21 Bn -8.04%
5 Novartis Ag 297.96 Bn 261.95 Bn 11.24 Bn 22.65%
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 16.30%
7 Amgen 235.44 Bn 190.84 Bn 7.24 Bn 23.62%
8 Gilead Sciences 190.69 Bn 164.89 Bn 6.22 Bn -134.51%
9 Pfizer 169.52 Bn 116.16 Bn 10.94 Bn -1.65%
10 Replimune 1.15 Bn 95.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -869.95%
Sep 30, 2018 -973.04%
Jun 30, 2018 -4,424.67%
Dec 31, 2017 -13,606.25%
Sep 30, 2017 -46,600.00%
Jun 30, 2017 -11,840.00%
API Access

Replimune Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY